A Phase 2 Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Adult Patients with Active Mild to Moderate Ulcerative Colitis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

August 1, 2027

Conditions

Ulcerative Colitis (UC)

Interventions

DRUG

Live SK08 powder

SK08 is an investigational live biotherapeutic product containing a nontoxigenic B. fragilis(NTBF) strain as an active ingredient.

DRUG

Placebo

All Listed Sponsors

lead

Guangzhou Zhiyi Biotechnology Co., Ltd.

OTHER